{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:48:23Z","timestamp":1793947703409,"version":"4.8.0"},"reference-count":70,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and tolerability of avacincaptad pegol (ACP), a Food and Drug Administration-approved therapy for geographic atrophy, administered in combination with ranibizumab, an approved therapy for neovascular age-related macular degeneration (nAMD), in patients with nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The phase 1 study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00709527\">NCT00709527<\/jats:ext-link>\n                      ) was a two-part, ascending-dose and parallel-group, open-label trial that assessed the safety, tolerability and pharmacokinetic profile of monthly intravitreal injections of ACP (0.03, 0.3, 1, 2, 3\u2009mg) in combination with ranibizumab (0.5\u2009mg) on the same day in treatment-na\u00efve patients with nAMD (n=43 patients received a maximum of 6 injections). The phase 2a study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03362190\">NCT03362190<\/jats:ext-link>\n                      ) was an open-label trial assessing the 6-month safety of intravitreal injections of ACP administered in combination with ranibizumab in treatment-na\u00efve patients with nAMD (n=64). Patients received either ACP 2\u2009mg or 4\u2009mg either 14 days or 1\u2009month apart, given on the same day or 2\u2009days after ranibizumab. Primary outcome measures were safety and tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the phase 1 study, there were no dose-limiting toxicities at any dose level. In both studies, ocular treatment-emergent adverse events were mostly mild or moderate, with the most reported events related to the injection procedure. There were no clinically significant increases in intraocular pressure or cumulative increases with multiple injections over time. There were no safety issues identified through measurement of visual acuity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coadministration of ACP and ranibizumab in treatment-na\u00efve patients with nAMD was well tolerated across different dosing regimens with no new safety issues based on results from two independent studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002232","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:10:22Z","timestamp":1770135022000},"page":"e002232","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-na\u00efve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct00709527","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03362190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00709527","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03362190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-4942","authenticated-orcid":false,"given":"Sunil S","family":"Patel","sequence":"first","affiliation":[{"name":"West Texas Retina Consultants, Abilene, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Boyer","sequence":"additional","affiliation":[{"name":"Retina-Vitreous Associates Medical Group, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[{"name":"Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel"},{"name":"Tel Aviv University, Tel Aviv-Yafo, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Clark","sequence":"additional","affiliation":[{"name":"Formerly, Astellas Pharma Inc, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Formerly, Astellas Pharma Inc, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Tang","sequence":"additional","affiliation":[{"name":"Formerly, Astellas Pharma Inc, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Desai","sequence":"additional","affiliation":[{"name":"Formerly, Astellas Pharma Inc, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026020308101767000_11.1.e002232.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"},{"key":"2026020308101767000_11.1.e002232.2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026020308101767000_11.1.e002232.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"2026020308101767000_11.1.e002232.4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.oret.2023.03.004","article-title":"Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration","volume":"7","author":"Blodi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"2026020308101767000_11.1.e002232.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00509-6"},{"key":"2026020308101767000_11.1.e002232.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100318","article-title":"Progression of Geographic Atrophy: Retrospective Analysis of Patients from the IRIS\u00ae Registry (Intelligent Research in Sight)","volume":"3","author":"Rahimy","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"2026020308101767000_11.1.e002232.7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.oret.2018.04.009","article-title":"Atrophy in Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 15","volume":"2","author":"Domalpally","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"2026020308101767000_11.1.e002232.8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00417-020-04892-5","article-title":"Central geographic atrophy vs. neovascular age-related macular degeneration: differences in longitudinal vision-related quality of life","volume":"259","author":"Ahluwalia","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.22599\/bioj.137","article-title":"Patient Perspectives in Geographic Atrophy (GA): Exploratory Qualitative Research to Understand the Impact of GA for Patients and Their Families","volume":"15","author":"Carlton","year":"2019","journal-title":"Br Ir Orthopt J"},{"key":"2026020308101767000_11.1.e002232.10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"key":"2026020308101767000_11.1.e002232.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-017-0514-3","article-title":"Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study","volume":"17","author":"Elshout","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ophtha.2019.12.009","article-title":"Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials","volume":"127","author":"Holekamp","year":"2020","journal-title":"Ophthalmology"},{"key":"2026020308101767000_11.1.e002232.13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OPTH.S226425","article-title":"Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use","volume":"14","author":"Patel","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.14","unstructured":"AAO . Age-Related Macular Degeneration Preferred Practice Pattern. Elsevier, 2019."},{"key":"2026020308101767000_11.1.e002232.15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","article-title":"The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration","volume":"132","author":"Sloan","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.16","unstructured":"SYFOVRE . Package Insert. Apellis Pharmaceuticals, Inc, 2024."},{"key":"2026020308101767000_11.1.e002232.17","unstructured":"IZERVAY . Package Insert. Astellas Pharma US, Inc, 2025."},{"key":"2026020308101767000_11.1.e002232.18","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.098426"},{"key":"2026020308101767000_11.1.e002232.19","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001392"},{"key":"2026020308101767000_11.1.e002232.20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review","volume":"36","author":"Desai","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026020308101767000_11.1.e002232.21","doi-asserted-by":"crossref","first-page":"100936","DOI":"10.1016\/j.preteyeres.2020.100936","article-title":"Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions","volume":"83","author":"Kim","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"2026020308101767000_11.1.e002232.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136851","article-title":"Complement System and Potential Therapeutics in Age-Related Macular Degeneration","volume":"22","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026020308101767000_11.1.e002232.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03796-9"},{"key":"2026020308101767000_11.1.e002232.24","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201591881"},{"key":"2026020308101767000_11.1.e002232.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00539","article-title":"C-Reactive Protein As a Mediator of Complement Activation and Inflammatory Signaling in Age-Related Macular Degeneration","volume":"9","author":"Chirco","year":"2018","journal-title":"Front Immunol"},{"key":"2026020308101767000_11.1.e002232.26","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000072"},{"key":"2026020308101767000_11.1.e002232.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.02.006"},{"key":"2026020308101767000_11.1.e002232.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.03.001"},{"key":"2026020308101767000_11.1.e002232.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110189"},{"key":"2026020308101767000_11.1.e002232.30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2578"},{"key":"2026020308101767000_11.1.e002232.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501536102"},{"key":"2026020308101767000_11.1.e002232.32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110359"},{"key":"2026020308101767000_11.1.e002232.33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jamaophthalmol.2013.713","article-title":"Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration: The Beaver Dam Eye Study","volume":"131","author":"Klein","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557"},{"key":"2026020308101767000_11.1.e002232.35","doi-asserted-by":"publisher","DOI":"10.1038\/ng1871"},{"key":"2026020308101767000_11.1.e002232.36","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr204"},{"key":"2026020308101767000_11.1.e002232.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.09.001"},{"key":"2026020308101767000_11.1.e002232.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.11.007"},{"key":"2026020308101767000_11.1.e002232.39","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1999.0798"},{"key":"2026020308101767000_11.1.e002232.40","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9587"},{"key":"2026020308101767000_11.1.e002232.41","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1072"},{"key":"2026020308101767000_11.1.e002232.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.491"},{"key":"2026020308101767000_11.1.e002232.43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.226266"},{"key":"2026020308101767000_11.1.e002232.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"2026020308101767000_11.1.e002232.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"2026020308101767000_11.1.e002232.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"2026020308101767000_11.1.e002232.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"2026020308101767000_11.1.e002232.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.023"},{"key":"2026020308101767000_11.1.e002232.49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000520171","article-title":"Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment","volume":"245","author":"Foss","year":"2022","journal-title":"Ophthalmologica"},{"key":"2026020308101767000_11.1.e002232.50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"key":"2026020308101767000_11.1.e002232.51","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.27448"},{"key":"2026020308101767000_11.1.e002232.52","unstructured":"U.S. FDA Approves Expanded Label for Astellas' IZERVAY\u2122 (avacincaptad pegol intravitreal solution) for Geographic Atrophy, Available: https:\/\/newsroom.astellas.us\/2025-02-12-U-S-FDA-Approves-Expanded-Label-for-Astellas-IZERVAY-TM-avacincaptad-pegol-intravitreal-solution-for-Geographic-Atrophy [Accessed 10 Mar 2025]."},{"key":"2026020308101767000_11.1.e002232.53","unstructured":"LUCENTIS . Package Insert. Genentech, Inc, 2018."},{"key":"2026020308101767000_11.1.e002232.54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40942-023-00517-1","article-title":"Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes","volume":"9","author":"Meyer","year":"2023","journal-title":"Int J Retina Vitreous"},{"key":"2026020308101767000_11.1.e002232.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.08.008"},{"key":"2026020308101767000_11.1.e002232.56","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-019-0157-z","article-title":"Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects","volume":"5","author":"Saxena","year":"2019","journal-title":"Int J Retina Vitreous"},{"key":"2026020308101767000_11.1.e002232.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"2026020308101767000_11.1.e002232.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2026020308101767000_11.1.e002232.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.10.047"},{"key":"2026020308101767000_11.1.e002232.60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/CIA.S2777","article-title":"Age-related macular degeneration and the aging eye","volume":"3","author":"Ehrlich","year":"2008","journal-title":"Clin Interv Aging"},{"key":"2026020308101767000_11.1.e002232.61","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12675"},{"key":"2026020308101767000_11.1.e002232.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.029"},{"key":"2026020308101767000_11.1.e002232.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.006"},{"key":"2026020308101767000_11.1.e002232.64","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1038\/s41598-021-87340-6","article-title":"Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease","volume":"11","author":"Tanaka","year":"2021","journal-title":"Sci Rep"},{"key":"2026020308101767000_11.1.e002232.65","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-016-0060-5","article-title":"Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD","volume":"13","author":"Lechner","year":"2016","journal-title":"Immun Ageing"},{"key":"2026020308101767000_11.1.e002232.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"2026020308101767000_11.1.e002232.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.012"},{"key":"2026020308101767000_11.1.e002232.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.12.002"},{"key":"2026020308101767000_11.1.e002232.69","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2026020308101767000_11.1.e002232.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.033"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:10:26Z","timestamp":1770135026000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjophth-2025-002232"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002232","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}